NCT07662330 Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia
| NCT ID | NCT07662330 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai 10th People's Hospital |
| Condition | Obesity & Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluate the effect of spermidine supplementation on lipid profile changes in individuals with overweight or obesity accompanied by hyperlipidemia. Analyze the impact of spermidine on metabolic parameters and assess the safety of spermidine supplementation, including liver and kidney function, gastrointestinal reactions, and other adverse effects.
Eligibility Criteria
Inclusion Criteria: * Males or females aged 18 to 65 years. * BMI ≥ 24 kg/m², without severe chronic diseases. * Not currently using glucose-lowering or lipid-lowering medications. * Dyslipidemia defined as triglycerides ≥ 1.7 mmol/L or total cholesterol ≥ 5.2 mmol/L. * No active weight loss or weight gain diet within the past 1 month. * No special dietary pattern changes (e.g., ketogenic, vegan, high-protein, meal replacement, intermittent fasting) within the past 1 month. * No use of supplements that may affect polyamine intake (e.g., germ, yeast, fermented extracts, nutritional powders) within the past 2-4 weeks. * Willing and able to provide signed informed consent. Exclusion Criteria: * Diagnosis of acute or severe gastrointestinal disease * Concurrent participation in any other weight-loss therapy * Current use of hypoglycemic or lipid-lowering medications * Participation in any other clinical trial within one month prior to signing the informed consent form * Pregnancy, lactation, or planning a pregnancy during the trial period * Known allergy to cellulose or wheat * History of cancer * Renal insufficiency, indicated by abnormal serum creatinine levels * Hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × upper limit of normal (ULN), or total bilirubin (TBIL) \>3 × ULN * Any other condition deemed by the investigator as inappropriate for trial participation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07662330 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Obesity & Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07662330 currently recruiting?
Yes, NCT07662330 is actively recruiting participants. Contact the research team at geyingjun@hotmail.com for enrollment information.
Where is the NCT07662330 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07662330 clinical trial?
NCT07662330 is sponsored by Shanghai 10th People's Hospital. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.